Sugi Predict

Sugi Predict / Compounds / SCHEMBL8270899

SCHEMBL8270899

SCHEMBL8270899

CC(C)C[C@H](NC(=O)c1cc2ccccc2s1)C(=O)N[C@@H]1CCCN(S(=O)(=O)c2ccccc2C#N)CC1=O

nearest known ligand 0.58

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 14/20 0.58
▸ CTSS P25774 7/20 0.55
▸ CTSL P07711 6/20 0.55
▸ CTSB P07858 5/20 0.55
▸ CTSV O60911 1/20 0.55
▸ UTS2R Q9UKP6 2/20 0.47
▸ TAS1R3 Q7RTX0 2/20 0.45
▸ TAS1R1 Q7RTX1 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5092564 1.00 CTSK (0.58) CTSKCTSSCTSLCTSBCTSV
SCHEMBL19617972 1.00 CTSK (0.58) CTSKCTSSCTSLCTSBCTSV
SCHEMBL19617971 1.00 CTSK (0.58) CTSKCTSSCTSLCTSBCTSV
SCHEMBL14391694 0.90 CTSK (0.61) CTSKCTSSCTSLCTSBCTSV
SCHEMBL5105653 0.89 CTSK (0.60) CTSKCTSSCTSLCTSBCTSV
SCHEMBL5105649 0.89 CTSK (0.60) CTSKCTSSCTSLCTSBCTSV
SCHEMBL14342616 0.89 UTS2R (0.54) CTSKCTSSCTSLCTSBCTSV
SCHEMBL4253479 0.89 UTS2R (0.54) CTSKCTSSCTSLCTSBCTSV
SCHEMBL5523428 0.89 UTS2R (0.54) CTSKCTSSCTSLCTSBCTSV
SCHEMBL4765295 0.88 CTSK (0.66) CTSKCTSSCTSLCTSBCTSV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11260049-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-03-01 — — US disclosed
US-11229623-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-01-25 — — US disclosed
US-20210299113-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-09-30 — — US disclosed
EP-3515887-B1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2021-07-07 — — EP disclosed
US-10968209-B2 TRPV4 antagonist GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED 2021-04-06 — — US disclosed
EP-3515888-B1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2021-03-31 — — EP disclosed
US-20200308160-A1 TRPV4 ANTAGONIST GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-10-01 — — US disclosed
US-20200261411-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-08-20 — — US disclosed
EP-3458451-B1 TRPV4 ANTAGONIST GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-06-03 — — EP disclosed
US-10588891-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-03-17 — — US disclosed
EP-3515887-A1 TRPV4 ANTAGONISTS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2019-07-31 — — EP disclosed
US-20190216774-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-18 — — US disclosed
US-20190202784-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-04 — — US disclosed
EP-3458451-A1 TRPV4 ANTAGONIST Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2019-03-27 — — EP disclosed
WO-2018055526-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
WO-2018055524-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
WO-2018055527-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
WO-2017199199-A1 TRPV4 ANTAGONIST GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-11-23 — — WO disclosed
US-20070259856-A1 Method for Activating Trpv4 Channel Receptors by Agonists SMITHKLINE BEECHAM CORPORATION 2007-11-08 — — US disclosed
WO-2006029209-A2 METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2006-03-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10968209-B2 TRPV4 antagonist TRPV4, TRPV1, TRPV5 CTSK 1070/4885CTSS 479/4885CTSL 1467/4885
US-20190202784-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 CTSK 2817/4885CTSS 2895/4885CTSL 2815/4885
US-11260049-B2 TRPV4 antagonists TRPV4, TRPV5, TRPV2 CTSK 2817/4885CTSS 2895/4885CTSL 2815/4885
US-20070259856-A1 Method for Activating Trpv4 Channel Receptors by Agonists TRPV4, TRPV2, TRPV3 CTSK 410/4885CTSS 492/4885CTSL 718/4885
US-20210299113-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 CTSK 2817/4885CTSS 2895/4885CTSL 2815/4885
US-20200308160-A1 TRPV4 ANTAGONIST TRPV4, TRPV1, TRPV5 CTSK 1070/4885CTSS 479/4885CTSL 1467/4885
US-10588891-B2 TRPV4 antagonists TRPV4, TRPV5, TRPV2 CTSK 2817/4885CTSS 2895/4885CTSL 2815/4885
US-11229623-B2 TRPV4 antagonists TRPV4, TRPV5, TRPV2 CTSK 2817/4885CTSS 2895/4885CTSL 2815/4885
US-20200261411-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 CTSK 2817/4885CTSS 2895/4885CTSL 2815/4885
US-20190216774-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 CTSK 2817/4885CTSS 2895/4885CTSL 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.